329,136 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Purchased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 329,136 shares of the biopharmaceutical company's stock, valued at approximately $15,483,000. Cytokinetics makes up 1.9% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s portfolio, making the stock its 25th biggest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned about 0.28% of Cytokinetics at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Jones Financial Companies Lllp raised its holdings in Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 374 shares during the last quarter. Retirement Systems of Alabama grew its position in shares of Cytokinetics by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 143,495 shares of the biopharmaceutical company's stock valued at $6,750,000 after purchasing an additional 565 shares during the period. Arizona State Retirement System grew its position in shares of Cytokinetics by 1.9% in the fourth quarter. Arizona State Retirement System now owns 32,366 shares of the biopharmaceutical company's stock valued at $1,522,000 after purchasing an additional 600 shares during the period. Inspire Investing LLC increased its stake in Cytokinetics by 7.8% in the fourth quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company's stock valued at $400,000 after purchasing an additional 616 shares during the last quarter. Finally, Centricity Wealth Management LLC purchased a new position in Cytokinetics during the fourth quarter worth about $29,000.

Cytokinetics Stock Up 0.2%

Shares of NASDAQ CYTK traded up $0.05 on Friday, hitting $30.54. The company had a trading volume of 1,789,501 shares, compared to its average volume of 1,620,482. The firm has a market capitalization of $3.65 billion, a P/E ratio of -5.68 and a beta of 0.81. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 12-month low of $29.31 and a 12-month high of $61.38. The business has a 50 day moving average of $37.58 and a two-hundred day moving average of $44.49.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, topping analysts' consensus estimates of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to analysts' expectations of $2.77 million. The firm's revenue was up 89.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.33) EPS. As a group, equities research analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Needham & Company LLC restated a "buy" rating and issued a $72.00 price target on shares of Cytokinetics in a report on Wednesday, May 14th. JMP Securities reissued a "market outperform" rating and issued a $78.00 target price on shares of Cytokinetics in a research report on Thursday, April 10th. UBS Group dropped their price target on shares of Cytokinetics from $47.00 to $41.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Barclays cut their price target on shares of Cytokinetics from $55.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Finally, Morgan Stanley set a $67.00 price objective on shares of Cytokinetics in a research note on Friday, March 7th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $74.73.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 3,341 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the sale, the executive vice president now owns 64,434 shares in the company, valued at $2,788,059.18. This trade represents a 4.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Wendall Wierenga sold 20,000 shares of Cytokinetics stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $38.46, for a total value of $769,200.00. Following the sale, the director now owns 24,848 shares in the company, valued at $955,654.08. This represents a 44.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 94,816 shares of company stock valued at $3,850,385. Corporate insiders own 2.70% of the company's stock.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.